Lipantyl 300 mg 30 capsules

Tradename:

Lipantyl

Lipantil

Compound:

Each capsule contains:

Fenofibrate 300 mg

Auxiliary components:

Sodium lauryl sulfate, lactose, starch, magnesium starate, gelatin, titanium dioxide, erythrosin.

Properties:

hypolipidemic drug. By activating PAPP-alpha (α-receptors activated by the peroxisome proliferator), fenofibrate enhances lipolysis and the excretion of atherogenic lipoproteins with a high content of triglycerides from the blood plasma by activating lipoprotein lipase and reducing the synthesis of apoprotein CIII. Activation of PAPP-alpha also leads to increased synthesis of apoproteins AI and AII.

Fenofibrate is a derivative of fibric acid, the ability of which to change the content of lipids in the human body is mediated by the activation of PAPP-alpha. The effects of fenofibrate on lipoproteins described above lead to a decrease in the content of the LDL and VLDL fractions, which include apoprotein B (apo B), and an increase in the content of the HDL fraction, which include apoprotein AI (apo AI) and apoprotein AII (apo AII).

Indications:

Used in combination with diet:

– simultaneously with HMG-CoA reductase inhibitors (statins) as part of combination therapy for mixed dyslipidemia (type lla, llb according to Fredrickson), in order to reduce triglycerides and increase HDL concentration in patients with coronary heart disease or at high risk of developing coronary artery disease (other clinical forms of atherosclerotic diseases: peripheral arterial atherosclerosis, abdominal aortic aneurysm and symptomatic carotid artery atherosclerosis, diabetes mellitus, multiple risk factors that correspond to a 10-year risk of developing coronary complications> 20%);

– in order to reduce the concentration of triglycerides in patients with severe hyperglyceridemia (dyslipidemia IV, V type according to Fredrickson);

– in order to reduce the elevated concentration of LDL, total cholesterol, triglycerides and apoB and increase the concentration of HDL in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson type lla, llb, III, IV).

Dosage and administration:

The average dose for adults is 1 capsule per day.

Contraindications:

– liver failure (including biliary cirrhosis and persistent liver dysfunction of unknown etiology);

– severe renal failure (CC <20 ml / min);

– chronic or acute pancreatitis, with the exception of cases of acute pancreatitis due to severe hypertriglyceridemia;

– history of gallbladder disease;

– a history of photosensitivity or phototoxicity during treatment with fibrates or ketoprofen;

– lactation period (breastfeeding);

– age up to 18 years (efficacy and safety have not been established);

– hypersensitivity to fenofibrate or other components of the drug.

Precautionary measures:

The effectiveness of therapy should be assessed by the content of lipids (total cholesterol, LDL, triglycerides) in the blood serum. In the absence of a therapeutic effect after several months of therapy (usually after 3 months), the advisability of prescribing concomitant or alternative therapy should be considered.

In patients with hyperlipidemia who are taking estrogens or hormonal contraceptives containing estrogen, it is necessary to determine whether the hyperlipidemia is primary or secondary. In such cases, the increase in lipid content may be caused by the intake of estrogens.

Side effects:

From the digestive system: often – abdominal pain, nausea, vomiting, diarrhea and moderate flatulence, a moderate increase in serum transaminase activity; infrequently – cases of pancreatitis, the formation of gallstones; very rarely – hepatitis. If symptoms of hepatitis appear (jaundice, pruritus), laboratory tests should be carried out and, if hepatitis is confirmed, fenofibrate should be discontinued.

From the musculoskeletal system: rarely – diffuse myalgia, myositis, muscle spasm and weakness; very rarely – rhabdomyolysis, increased CPK activity.

From the side of the cardiovascular system: infrequently – venous thromboembolism (pulmonary embolism, deep vein thrombosis).

On the part of the hematopoietic system: rarely – an increase in hemoglobin and leukocytes.

From the nervous system: rarely – headache.

From the respiratory system: very rarely – interstitial pneumopathy.

From the reproductive system: rarely – sexual dysfunction.

Storage method:

Store at a temperature not exceeding 30 degrees. In a dry place.

Package:

The cardboard box contains 1,2 or 3 blisters of 10 capsules.